Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor‐like kinase‐2 (ALK2) inhibitor, in healthy participants

Documenti analoghi

• Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
  di: Yan‐ou Yang, et al.
  Pubblicazione: (2025)
• Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
  di: Yan‐ou Yang, et al.
  Pubblicazione: (2025)
• The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review
  di: Hansa Mreyoud, et al.
  Pubblicazione: (2024)
• Effect of proton pump inhibitors versus histamine‐2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers
  di: Hua‐Ping Fan, et al.
  Pubblicazione: (2024)
• Comparative Bioequivalence Study of 2 Clevidipine Formulations in Healthy Chinese participants: A Single‐Dose, 2‐Period Crossover Trial
  di: Zhuo Chen, et al.
  Pubblicazione: (2025)